Mixed suspension, mixed product removal
(MSMPR) crystallizers are
widely implemented for the continuous crystallization of active pharmaceutical
ingredients (APIs), allowing enhanced efficiency, flexibility, and
product quality compared to currently dominant batch crystallizer
designs. Establishing cost-effective continuous crystallization process
configurations for societally and economically important APIs is essential
to ensure the successful implementation of end-to-end continuous pharmaceutical
manufacturing (CPM) campaigns. Process modeling and optimization allow
rapid, systematic comparative technoeconomic evaluations. This paper
pursues total cost minimization of different crystallizer configurations
of three APIscyclosporine, paracetamol, and aliskiren hemifumaratewhose
continuous MSMPR crystallization has been experimentally demonstrated.
Nonlinear optimization for total cost minimization is implemented
for one to three crystallizers for different plant API capacities
with crystallizer temperatures and residence times as decision variables.
Optimization results show that the optimal number of crystallizers
is dependent on plant capacity; implementing one crystallizer is preferred
for all three APIs at 102 kg year–1,
while multiple crystallizer implementation is more cost-beneficial
at increased capacities. These trends are observed due to the increasing
dominance of operating expenditures on total costs at increased capacities,
making the benefits of implementing more crystallizers (enhanced yields,
reduced utility loads) worth the increased capital expenditures. Process
modeling and optimization allows rapid technoeconomic evaluation of
MSMPR crystallizer configurations for different APIs toward systematic
selection of optimal continuous crystallizer designs for continuous
manufacturing.